Vivos Therapeutics, Inc. (NASDAQ:VVOS) Short Interest Update

Vivos Therapeutics, Inc. (NASDAQ:VVOS) was the target of a large increase in short interest during the month of November. As of November 15th, there was short interest totalling 130,800 shares, an increase of 37.5% from the October 31st total of 95,100 shares. Based on an average daily volume of 1,360,000 shares, the short-interest ratio is presently 0.1 days. Currently, 3.0% of the shares of the stock are sold short.

Vivos Therapeutics Price Performance

VVOS opened at $3.41 on Friday. The company’s 50 day moving average price is $2.80 and its two-hundred day moving average price is $2.57. The firm has a market capitalization of $16.50 million, a price-to-earnings ratio of -0.60 and a beta of 7.71. Vivos Therapeutics has a fifty-two week low of $1.91 and a fifty-two week high of $31.50.

Analysts Set New Price Targets

VVOS has been the subject of several research analyst reports. Ascendiant Capital Markets reiterated a “buy” rating and set a $6.60 price target on shares of Vivos Therapeutics in a report on Wednesday, November 20th. Alliance Global Partners lowered their target price on Vivos Therapeutics from $8.25 to $6.00 and set a “buy” rating for the company in a report on Tuesday, November 19th.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.